Abbott Laboratories (ABT)
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%
Weekly Jobless Claims continue to portray a labor market cruising along at a healthy low rate of unemployment claims.
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls
ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition and diagnostics sales.
Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Matches Q4 Earnings Estimates
Abbott (ABT) came out with quarterly earnings of $1.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.34 per share a year ago.
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
2 Healthcare Names That Could Get a Big Boost From Earnings
Active traders expect companies in the healthcare sector to experience significant share price spikes tied to milestones in the development of new therapies and medical products. The volatility in some corners of the sector makes it a high-risk, but high-reward, opportunity.
Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
ABT heads into Q4 earnings with adult nutrition in focus, as Ensure and Glucerna launches are expected to support modest segment growth.
Abbott Laboratories: Q4 Earnings On The Horizon
Abbott Laboratories has been essentially flat over the last 15 months, underperforming the S&P 500's 17.5% total return. Q3 2025 results showed normalized EPS in line at $1.30, with revenue up nearly 7% year-over-year, but missing consensus by $20M. Most of the segments saw healthy increases, particularly in the International regions in Q3; hopefully, we'll see the same in Q4 next week.
Abbott (ABT) Declines More Than Market: Some Information for Investors
Abbott (ABT) closed at $121.76 in the latest trading session, marking a -1.43% move from the prior day.
Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
